Skip to main content

Fiscal Wizard · Single-issue tearsheet

GRFS / Jun 22, 2026 Run #7643

GRFS

Grifols, S.A.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Composite verdict

F 20.1 / 100
Bearish setup · Trend Following 11 drivers · 6 gates blocking
  • Stochastic RSI
  • Double 7s
  • Vortex Signal
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 15th of 22 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 20 signals100% Bear
Momentum Bearish 10Mean-reversion Bearish 40

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -12%
Asset value $20.41Earnings power value $9.82Price $7.40

Trading below its asset value ($20.41/share) — deep value, but check for a melting balance sheet.

Fundamentals Mixed

40.2 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Free Cash Flow Yield 100
OCF to Net Income 0
Forward P/E 85
Inventory Turnover 0
Days Sales Outstanding 83
Cash Conversion Cycle 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Stochastic RSI, Double 7s, Vortex Signal); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Vortex Signal 17
Stochastic RSI 17
Double 7s 18

Risk Gates

6 blocking 3 caution

6 guards active, 20 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Debt-to-Equity Blocking

High debt-to-equity blocks bullish signals — leverage risk.

Net Debt / EBITDA Blocking

High net debt / EBITDA blocks bullish signals — credit-leverage risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for GRFS.